Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published Date March 2010 Volume 2010:6 Pages 145—155

DOI http://dx.doi.org/10.2147/VHRM.S8216

Published 9 March 2010

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway

Chen X, Zhouhua W, Jie Z, Xinlu F, Jinqiang L, Yuwen Q, Zhiying H

International Journal of Nanomedicine 2015, 10:1-22

Published Date: 18 December 2014

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Eickels MV, Turpie AGG

Vascular Health and Risk Management 2014, 10:425-434

Published Date: 17 July 2014

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Erratum

Krikeli M, Ekonomopoulou MT, Tzitzikas I, Goutzioulis A, Mystakidou K, Pistevou-Gompaki K

Cancer Management and Research 2011, 3:319-320

Published Date: 5 December 2011

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues AN, Coelho LC, Goncalves WLS, Gouvea SA, Vasconcellos MJR, Cunha RS, Abreu GR

Vascular Health and Risk Management 2011, 7:375-381

Published Date: 9 June 2011

3D culture of adult mouse neural stem cells within functionalized self-assembling peptide scaffolds

Cunha C, Panseri S, Villa O, Silva D, Gelain F

International Journal of Nanomedicine 2011, 6:943-955

Published Date: 2 May 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials

Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia

Vascular Health and Risk Management 2009, 5:411-427

Published Date: 8 May 2009